Chemotherapy, radiation therapy, and surgical intervention have been the primary modalities for cancer treatment in the past few decades (Liu et al., 2024). Although these therapies often show short-term effectiveness, they exhibit many significant drawbacks, including toxicity, a lack of specificity, and the emergence of drug resistance. The scientific community is now exploring alternative ways that could provide more specific, persistent results with reduced undesirable consequences (Anand et al., 2022).
Immunotherapy is an innovative approach that has attracted significant attention and has emerged as a potent instrument in the fight against cancer (Zhang et al., 2025). The basic principle of immunotherapy is simple but effective: using the human body immune system to identify, target, and eliminate cancer and proliferating cells. This technique has the potential for sustained disease management by utilizing the immune system’s inherent ability to differentiate between healthy and aberrant cells and to adapt its response over time (Zhang et al., 2025).
Chimeric antigen receptor (CAR)-T cell therapy has transformed targeted immunotherapy, facilitating the treatment of both haematologic and solid tumours, in addition to non-oncologic disorders (Patel et al., 2025). This innovative therapy originated from years of progressive developments in cell-based therapeutics and continues to advance to address significant challenges. The progress in immunotherapy is highlighted in this Research Topic, Current Trends in Immunotherapy: From Monoclonal Antibodies to CAR-T Cells. It addresses progress from innovative cellular therapies like CAR-T cells to treatments based on monoclonal antibodies. The included articles illustrate how the future of immune-based treatments is being affected by developments in genetics, bioengineering, and molecular biology (Figure 1).
FIGURE 1
A variety of investigations focus on the interactions between immune cells and cancer cells, providing new insights into how tumors evade immune identification and strategies to counteract these evasion mechanisms (Wu et al., 2024). Others concentrate on the development of immune checkpoint inhibitors, which have revolutionised the management of malignancies such as renal cell carcinoma, non-small cell lung cancer, and melanoma. This chapter also addresses the increasing prominence of personalised vaccinations, oncolytic viruses, and bispecific antibodies (Khosravi et al., 2024).
CAR-T cell therapy, wherein a patient’s T cells are genetically modified to identify and target cancer, is among the most interesting and complex subjects addressed (Kirouac et al., 2023). Initially developed for haematological malignancies, research is currently broadening its use to solid tumours, addressing challenges such as antigen heterogeneity and inhibition by the tumour microenvironment (Kirouac et al., 2023).
This Research Topic of essays emphasises the progress and promise of immunotherapy as a robust and adaptable cancer treatment approach. They highlight ongoing challenges that must be addressed to fully actualise the potential of immunotherapy, including immune-related toxicities, variability in patient responses, and the substantial expense of certain medicines.
Immunotherapy is now considered a validated treatment mode. It is now strongly recognized as the fourth pillar of cancer treatment, alongside radiation, chemotherapy, and surgery (Tagliabue et al., 2018). Immunotherapy is expected to have increasing significance in personalized and precision oncology as research advances our understanding of the immune system and its interactions with cancer (Tagliabue et al., 2018). This Research Topic serves as a resource for researchers, physicians, and students, encapsulating a specific point in the growth of the field.
Statements
Author contributions
KP: Writing – original draft, Writing – review and editing. MG: Writing – review and editing.
Funding
The author(s) declare that no financial support was received for the research and/or publication of this article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that GenerativeAI was used in the creation of this manuscript. The author(s) verify and take full responsibility for the use of generative AI in the preparation of this manuscript. Generative AI was used QuillBot and ChatGPT were utilised for grammar checking and proofreading.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AnandU.DeyA.ChandelA. K. S.SanyalR.MishraA.PandeyD. K.et al (2022). Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis.10, 1367–1401. 10.1016/j.gendis.2022.02.007
2
KhosraviG.-R.MostafaviS.BastanS.EbrahimiN.GharibvandR. S.EskandariN. (2024). Immunologic tumor microenvironment modulators for turning cold tumors hot. Cancer Commun. lond. Engl.44, 521–553. 10.1002/cac2.12539
3
KirouacD. C.ZmurchokC.DeyatiA.SichermanJ.BondC.ZandstraP. W. (2023). Deconvolution of clinical variance in CAR-T cell pharmacology and response. Nat. Biotechnol.41, 1606–1617. 10.1038/s41587-023-01687-x
4
LiuB.ZhouH.TanL.SiuK. T. H.GuanX.-Y. (2024). Exploring treatment options in cancer: tumor treatment strategies. Signal Transduct. Target. Ther.9, 175–244. 10.1038/s41392-024-01856-7
5
PatelK. K.TariveranmoshabadM.KaduS.ShobakiN.JuneC. (2025). From concept to cure: the evolution of CAR-T cell therapy. Mol. Ther.33, 2123–2140. 10.1016/j.ymthe.2025.03.005
6
TagliabueL.CapozzaA.MaioliC.LucianiA.IerardiA. M.CarrafielloG. (2018). Immunotherapy treatment: an issue for metabolic response. Q. J. Nucl. Med. Mol. Imaging Off. Publ. Ital. Assoc. Nucl. Med. AIMN Int. Assoc. Radiopharm. IAR Sect. Soc.62, 140–151. 10.23736/S1824-4785.17.03035-7
7
WuB.ZhangB.LiB.WuH.JiangM. (2024). Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct. Target. Ther.9, 274. 10.1038/s41392-024-01979-x
8
ZhangM.LiuC.TuJ.TangM.AshrafizadehM.NabaviN.et al (2025). Advances in cancer immunotherapy: historical perspectives, current developments, and future directions. Mol. Cancer24, 136. 10.1186/s12943-025-02305-x
Summary
Keywords
immunotherapy, monoclonal antibodies, CAR-T cells, cancer therapy, targeted therapy
Citation
Pant K and Glassy MC (2025) Editorial: Current trends in immunotherapy: from monoclonal antibodies to CAR-T cells. Front. Mol. Med. 5:1633469. doi: 10.3389/fmmed.2025.1633469
Received
22 May 2025
Accepted
26 May 2025
Published
02 June 2025
Volume
5 - 2025
Edited and reviewed by
Masaru Katoh, National Cancer Center, Japan
Updates
Copyright
© 2025 Pant and Glassy.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Kishor Pant, kpant@umn.edu; Mark C. Glassy, markglassy@aol.com
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.